<DOC>
	<DOCNO>NCT02332447</DOCNO>
	<brief_summary>Sudden unexpected death epilepsy ( SUDEP ) primarily affect young adult drug-resistant epilepsy , incidence 0.4 % /year . The diagnosis SUDEP require anamnestic data post-mortem examination reveal structural toxicological cause death . Generalized tonic-clonic seizure ( GTCS ) main risk factor SUDEP , appear trigger instance . Indeed , experimental clinical data strongly suggest SUDEP result postictal respiratory dysfunction progress terminal apnea , later follow cardiac arrest . Postictal apnea could partly derive seizure-induced massive release endogenous opioids . Animal study suggest seizure-related release endogenous opioid peptide participate termination seizure . In patient epilepsy , functional imaging study confirm seizure induce release endogenous opioids . The brainstem respiratory center contain high density opioid receptor , account respiratory depression one cardinal symptom opioid overdose . The investigator hypothesis SUDEP partly result post-ictal apnea promote GTCS-induced massive release endogenous opioids , opioid antagonist could represent effective preventive treatment SUDEP . This could achieve chronic administration Naltrexone , opioid antagonist use large population patient chronic alcoholism high risk seizure , without show pro-convulsant effect . This crucial feasibility issue since antagonise mechanism think participate seizure termination could theoretically aggravate seizure . Before evaluate efficacy chronic administration naltrexone , legitimate perform proof concept study test acute effect equivalent injectable treatment ( Naloxone ) immediate aftermath GTCS record inhospital video-EEG monitoring patient refractory epilepsy . One third patient develop postictal respiratory dysfunction hypoxemia , reduce investigator intervention investigator hypothesis correct . The main objective study evaluate efficacy 0.4 mg intravenous naloxone , versus placebo , administer immediate aftermath GTCS , reduce severity postictal central respiratory dysfunction occur end seizure , measure pulse oximetry . About 25 % patient drug-resistant partial epilepsy undergo long-term video-EEG monitoring develop least one partial secondary generalize tonic-clonic seizure . However , patient individualize priori . Therefore , adult patient drug-resistant epilepsy undergo long-term video-EEG monitor one participate centre , lack exclusion criterion , give write informed consent participate study develop GTCS , include study . They benefit continuous monitoring pulse oximetry ( together video , EEG , respiration recording ) , equip peripheral venous catheter throughout video-EEG . The modality video-EEG monitoring consistent current practice similar across 14 centre ( apart venous catheter standard practice ) . In case occurrence generalize tonic-clonic seizure , patient randomize ( 1:1 ) receive intravenous naloxone ( 0.4 mg ) placebo . Placebo isotonic sodium chloride preparation packaging centralized ensure indistinguishability naloxone . Randomization centralize stratified centre . The evolution partial seizure GTCS gradual , total duration seizure range 2 3 minute , injection prepare course seizure . Given assumption role endogenous opioids release spontaneous termination seizure , naloxone administrate immediately end GTCS . All digital data ( video , EEG , respiration , SpO2 ) centralize evaluate blind data PI study involve video-EEG monitoring include patient . The automatic objective analysis SpO2 data one already developed PHRC REPOMSE perform .</brief_summary>
	<brief_title>Efficacy Naloxone Reducing Postictal Central Respiratory Dysfunction Patients With Epilepsy</brief_title>
	<detailed_description>Sudden unexpected death epilepsy ( SUDEP ) primarily affect young adult drug-resistant epilepsy , incidence 0.4 % /year . The diagnosis SUDEP require anamnestic data post-mortem examination reveal structural toxicological cause death . Generalized tonic-clonic seizure ( GTCS ) main risk factor SUDEP , appear trigger instance . Indeed , experimental clinical data strongly suggest SUDEP result postictal respiratory dysfunction progress terminal apnea , later follow cardiac arrest . Postictal apnea could partly derive seizure-induced massive release endogenous opioids . Animal study suggest seizure-related release endogenous opioid peptide participate termination seizure . In patient epilepsy , functional imaging study confirm seizure induce release endogenous opioids . The brainstem respiratory center contain high density opioid receptor , account respiratory depression one cardinal symptom opioid overdose . Our hypothesis SUDEP partly result post-ictal apnea promote GTCS-induced massive release endogenous opioids , opioid antagonist could represent effective preventive treatment SUDEP . This could achieve chronic administration Naltrexone , opioid antagonist use large population patient chronic alcoholism high risk seizure , without show pro-convulsant effect . This crucial feasibility issue since antagonise mechanism think participate seizure termination could theoretically aggravate seizure . Before evaluate efficacy chronic administration naltrexone , legitimate perform proof concept study test acute effect equivalent injectable treatment ( Naloxone ) immediate aftermath GTCS record inhospital video-EEG monitoring patient refractory epilepsy . One third patient develop postictal respiratory dysfunction hypoxemia , reduce investigator intervention investigator hypothesis correct . The main objective study evaluate efficacy 0.4 mg intravenous naloxone , versus placebo , administer immediate aftermath GTCS , reduce severity postictal central respiratory dysfunction occur end seizure , measure pulse oximetry . About 25 % patient drug-resistant partial epilepsy undergo long-term video-EEG monitoring develop least one partial secondary generalize tonic-clonic seizure . However , patient individualize priori . Therefore , adult patient drug-resistant epilepsy undergo long-term video-EEG monitor one participate centre , lack exclusion criterion , give write informed consent participate study develop GTCS , include study . They benefit continuous monitoring pulse oximetry ( together video , EEG , respiration recording ) , equip peripheral venous catheter throughout video-EEG . The modality video-EEG monitoring consistent current practice similar across 14 centre ( apart venous catheter standard practice ) . In case occurrence generalize tonic-clonic seizure , patient randomize ( 1:1 ) receive intravenous naloxone ( 0.4 mg ) placebo . Placebo isotonic sodium chloride preparation packaging centralized ensure indistinguishability naloxone . Randomization centralize stratified centre . The evolution partial seizure GTCS gradual , total duration seizure range 2 3 minute , injection prepare course seizure . Given assumption role endogenous opioids release spontaneous termination seizure , naloxone administrate immediately end GTCS . All digital data ( video , EEG , respiration , SpO2 ) centralize evaluate blind data PI study involve video-EEG monitoring include patient . The automatic objective analysis SpO2 data one already developed PHRC REPOMSE perform .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>For inclusion Adult patient ( ≥ 18 year ) suffer drugresistant partial epilepsy Patient undergo longterm videoEEG monitor one participate centre record characterize seizure Patient give write informed consent participate study For randomization Patient suffers secondary generalize tonicclonic seizure longterm videoEEG monitoring supervise nurse physician Age &lt; 18 year Pregnant breastfeed woman Hypersensitivity naloxone History severe heart disease ( myocardial infarction , heart failure disorder , arrhythmia severe hypertension ) Ongoing opioïd treatment , include pure agonists partial agonist Addiction opioïds , heroin , similar substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Tonic-clonic seizure</keyword>
	<keyword>Naloxone</keyword>
	<keyword>SUDEP</keyword>
</DOC>